Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiation into myofibroblasts
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Tissue fibrosis, the excessive deposition of collagen/extracellular matrix combined with the reduction of the cell compartment, defines fibroproliferative diseases, a major cause of death and a public health burden. Key cellular processes in fibrosis include the generation of myofibroblasts from progenitor cells, and the activation or switch of already differentiated cells to a fibrotic synthetic phenotype. Myostatin, a negative regulator of skeletal muscle mass, is postulated to be involved in muscle fibrosis. We have examined whether myostatin affects the differentiation of a multipotent mesenchymal mouse cell line into myofibroblasts, and/or modulates the fibrotic phenotype and Smad expression of the cell population. In addition, we investigated the role of follistatin in this process. Incubation of cells with recombinant myostatin protein did not affect the proportion of myofibroblasts in the culture, but significantly upregulated the expression of fibrotic markers such as collagen and the key profibrotic factors transforming growth factor-β1 (TGF-β1) and plasminogen activator inhibitor (PAI-1), as well as Smad3 and 4, and the pSmad2/3. An antifibrotic process evidenced by the upregulation of follistatin, Smad7, and matrix metalloproteinase 8 accompanied these changes. Follistatin inhibited TGF-β1 induction by myostatin. Transfection with a cDNA expressing myostatin upregulated PAI-1, whereas an shRNA against myostatin blocked this effect. In conclusion, myostatin induced a fibrotic phenotype without significantly affecting differentiation into myofibroblasts. The concurrent endogenous antifibrotic reaction confirms the view that phenotypic switches in multipotent and differentiated cells may affect the progress or reversion of fibrosis, and that myostatin pharmacological inactivation may be a novel therapeutic target against fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866
Singh, R., Artaza, J. N., Taylor, W. E., Gonzalez-Cadavid, N. F., & Bhasin, S. (2003) · Endocrinology · doi:10.1210/en.2003-0741 · Cited by 555
Self-citationFollistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis
Amthor, H., Nicholas, G., McKinnell, I., Kemp, C. F., Sharma, M., Kambadur, R., & Patel, K. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2004.01.046 · Cited by 401
Singh, R., Artaza, J. N., Taylor, W. E., Braga, M., Yuan, X., Gonzalez-Cadavid, N. F., & Bhasin, S. (2006) · Endocrinology · doi:10.1210/en.2004-1649 · Cited by 369
Self-citationSignal transduction of inflammatory cytokines and tumor development
Yoshimura, A. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00197.x · Cited by 314 · cited 1×
“2007), and TNF-a is associated with fibrotic processes (Yoshimura 2006).”
BackgroundLiver fibrosis: cellular mechanisms of progression and resolution
Henderson, N. C., & Iredale, J. P. (2007) · Clinical Science · doi:10.1042/cs20060242 · Cited by 270
Zhu, X., Topouzis, S., Liang, L.-F., & Stotish, R. L. (2004) · Cytokine · doi:10.1016/j.cyto.2004.03.007 · Cited by 230 · cited 3×
“This is likely to occur via the Smad pathway, since myostatin signals through Smad2–4, and phosphorylates Smad3 (Zhu et al. 2004).”
BackgroundInfluentialKrieg, T., Abraham, D., & Lafyatis, R. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2188 · Cited by 151
Cited by
Garcia, L. A., King, K. K., Ferrini, M. G., Norris, K. C., & Artaza, J. N. (2011) · Endocrinology · doi:10.1210/en.2011-0159 · Cited by 263
Self-citationThe origin of intermuscular adipose tissue and its pathophysiological implications
Vettor, R., Milan, G., Franzin, C., Sanna, M., De Coppi, P., Rizzuto, R., & Federspil, G. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00229.2009 · Cited by 261
Gonzalez-Cadavid, N. F. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01195.x · Cited by 172
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Profibrotic Role of Myostatin in Peyronie's Disease
Cantini, L. P., Ferrini, M. G., Vernet, D., Magee, T. R., Qian, A., Gelfand, R. A., Rajfer, J., & Gonzalez-Cadavid, N. F. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00847.x · Cited by 59
Self-citation
Metadata
- Authors
- Artaza, J. N., Singh, R., Ferrini, M. G., Braga, M., Tsao, J., & Gonzalez-Cadavid, N. F.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2007-11-07
- Volume
- 196
- Issue
- 2
- Pages
- 235-249
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2127212961
- Cited by
- 51
- References
- 9
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiation into myofibroblasts. https://app.cochat.ai/papers/10.1677/joe-07-0408
- The paper
- Artaza, J. N., Singh, R., Ferrini, M. G., Braga, M., Tsao, J., & Gonzalez-Cadavid, N. F. (2008). Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiation into myofibroblasts. Journal of Endocrinology. https://doi.org/10.1677/joe-07-0408
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.